Treatment variation in early breast cancer in the UK. by Dodwell, David et al.
Treatment variation in early breast cancer in the UK
David Dodwell and colleagues examine why treatment variation continues to occur in breast cancer
despite high quality evidence on best practice
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Kieran Horgan7
One in seven women will develop breast cancer.
Although the number of people diagnosed with this
common disease is increasing, mortality continues
to fall. In the UK, almost 80% of women diagnosed
with breast cancer are alive 10 years after their initial
diagnosis.1 The survival gains seen over recent
decades have largely been achieved through earlier
diagnosis andmoreeffective treatments.Nonetheless,
there is still room for improvement. Populationbased
mortality for breast cancer among those aged <75
years in the UK ranges from 13 to 32 per 100 000,2 and
UK survival rates from breast cancer are still reported
to be below those in countries such as the United
States and Australia.3
The treatment of breast cancer is multimodal,
comprising local treatment (surgery and
radiotherapy) and systemic treatments (endocrine
therapy, chemotherapy, and biological therapy).
Breast conserving surgery is, in most cases preferred
to mastectomy (removal of all the breast tissue)
providing equivalent oncological outcomes, butwith
quality of life benefits. The choice of systemic
therapies is driven by risk of recurrence, determined
by stage, grade, and molecular pathological
characteristics. For example, patients with ER
(oestrogen receptor) positive cancer are treated with
endocrine therapy and those with HER2 (human
epidermal growth factor receptor 2) positive disease
commonly receive trastuzumab and chemotherapy.
Although randomised controlled trials haveprovided
good evidence for optimal treatment, variation still
occurs in the UK and may be one factor in reported
lower survival rates.
Treatment variation
Surgery is the most important treatment for early
breast cancer. The 2018 National Institute for Health
and Care Excellence (NICE) guidelines maintain that
patients should be treated “irrespective of age, with
surgery and appropriate systemic therapy, rather
than endocrine therapy alone, unless significant
comorbidity precludes surgery.”4
However, theNationalAudit of Breast Cancer inOlder
Patients has shown important differences among
hospitals in the surgical care of older patients in
England and Wales. For patients diagnosed between
2014 and 2016, rates of surgery varied from 85% to
100% (mean 96%) in those aged 50-69 and from 46%
to 97% (mean 76%) in those aged ≥70.5 Among the
same cohort, rates of breast conserving surgery were
46-85% in patients aged 50-69 and 22-77% in those
aged ≥70 (table 1).
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Table 1 | Reported variation in care for early breast cancer
Effect of variationReported variation in rates (%)Years of studyExample
Surgical care
Reduced survival, higher risk of locoregional
failure
Patients aged 50-69: 85-100% (mean 96%)
Patients aged ≥70: 46-97% (mean 76%)*†
2014-165Rate of surgery overall
Loss of quality of life and psychological
wellbeing in patients denied an opportunity for
breast conservation surgery
Patients aged 50-69: 46-85%
Patients aged ≥70: 22-77%*
2014-165Rate of breast conservation v mastectomy
47-64% at regional level; 8-81% at surgeon
level
20146
Loss of quality of life; need for additional or
delayed surgical reconstruction treatment
5-70% (mean 28%) for invasive disease.
10-100% (mean 49%) for non-invasive
disease*
2017-187Use of mastectomy with immediate breast
reconstruction
4-37% (mean 10%) for all patients ‡2000-148
9-43% (mean: 21% overall, 38% for ductal
carcinoma in situ, 17% for invasive disease)‡
2008-099
Increased risk of locoregional and distant
recurrence
48-91%*†2014-1710Use of initial surgery v primary endocrine
therapy in ER+ disease
Adjuvant treatment
Higher locoregional recurrence risk, need for
further surgery and other treatments, survival
disadvantage in higher risk patients
Patients aged 50-69: 69% to 99% after breast
conservation surgery; 32%-100% after
mastectomy in patients aged 50-69
Patients aged ≥70: 60%-97% after breast
conservation; 19-90% after mastectomy*
2014-1711Use of radiotherapy after surgery for invasive
disease
Higher local recurrence risk, greater need for
subsequent surgery
0-100% (median 58%) at screening unit level2003-0612Use of radiotherapy after breast conserving
surgery for DCIS
Higher risk of distant metastatic disease,
compromised survival
Patients aged 50-69: 7-95%
Patients aged ≥70: 11-72%*†
2014-1711 13Use of trastuzumab and chemotherapy for
HER2 positive disease
* Trust level, †Adjusted rates, ‡Cancer network level. DCIS=ductal carcinoma in situ.
These contemporary examples mirror the variation in patterns of
surgical practice seen around 20 years ago. The Breast Cancer
Clinical Outcomes Measure Audit of symptomatically presenting
breast cancer reported mastectomy rates that varied from 36% to
53%, and 19% to 92% at regional and individual surgeon level,
respectively.6
Older patients with ER positive early breast cancer may receive
primary endocrine therapy (PET) rather than initial surgery for valid
reasons—for example, serious comorbidity or short life expectancy.
Figure 1 shows thepercentage ofwomen inEnglandandWales aged
≥70 years receiving initial surgical treatment by NHS organisation
and ER status. Substantial organisational variation occurred for
women with ER positive cancer but not those with ER negative
disease.10 This variation remained after adjustment for comorbidity
and frailty, suggesting that different perceptions of appropriate
care for women with ER positive disease may be responsible.14
Randomised controlled trials have found that primary endocrine
therapy has inferior outcomes for local control and disease-free
survival compared with initial surgery,15 and overuse of primary
endocrine therapy may be associated with the poorer relative
survival seen in theUKcomparedwithother Europeancountries.1617
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Fig 1 | Risk adjusted percentage (95% confidence interval) of women aged ≥70 years receiving surgery as first treatment for early invasive breast cancer, by NHS organisation
in Wales and England and oestrogen receptor (ER) status (redrawn with permission from HQIP)
10
Substantial variation in clinical management extends to the use of
radiotherapy,11 12 18 adjuvant systemic therapy,10 13 and immediate
breast reconstruction.7 -9 (table 1).
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Causes of treatment variation
Many reports have highlighted inequalities in breast cancer care
based on age, geography, ethnicity, and disability,2 3 8 10 17 but
variation in the delivery of treatment persists even after trying to
account for these factors. Furthermore, given the magnitude of
variation across treatment methods, its persistence over time, and
the large numbers of patients involved, the influence of factors such
as patient preference or poor data quality is likely to be small.
The combinationof risingbreast cancer incidence andan increasing
number of complex treatments has placed substantial demand on
resources, and this may have contributed to variations in care.19 20
In England, the 2012 Health and Social Care Act led to the
introduction of clinical commissioning groups. Although these
groups were intended to improve the delivery and rationalisation
of health services for diverse local populations, they also created
an opportunity for differential introduction of new treatments
because of disparities in local commissioning priorities and
processes. This was seen with the introduction of adjuvant
bisphosphonates after the identification of significant benefit in
post-menopausal women.21 Bisphosphonates are inexpensive and
yet there was prolonged geographical variation in their availability.
It took three to four years from the publication of a definitive
meta-analysis confirming benefit before prescribing in the UK
became uniform.22 23
Although multidisciplinary teams should mitigate the effect of
individual clinician preferences, clinicians may still be influenced
by local practice, their involvement in clinical research, and the
influence of their seniors. Several prominent trials of primary
endocrine therapy occurred during the 1990s and 2000s, and these
may have unduly influenced subsequent UK practice.24 -26
How to reduce variation in care
Unexplained variation in care is not a new problem and has a
reported history of over 80 years, encompassing a huge range of
medical interventions.27 There are, however,many reasons to expect
greater uniformity in the care of patients with early breast cancer
in the UK. These include the NHS principle of equitable healthcare,
the volumeandaccessibility of highquality published trial evidence,
the emphasis on multidisciplinary approaches to care, the quality
assurance processes for screen detected disease, the long history
of national audits (see supplementary data on bmj.com), and, until
recently, national cancer peer review.
NICE offers advice on the principles and practice of shared decision
making, but its guidance that a treatment be “offered” (strong
recommendation) or “considered” (less certain benefit) is arguably
open to variable interpretation.Other countries differ in the strength
of their advice. In Denmark treatments are “recommended.”
Radiotherapy inuniformdoseand fractionation is routinelyprovided
after mastectomy for node positive invasive disease or breast
conserving surgery. Deviations from national recommendations
require explicit explanation in the patient’s medical records and
noting in the Danish Breast Cancer Group database. Jensen and
colleagues reported that compliance with new or changed Danish
breast cancer guidelines was over 90% within an average of one to
two years.28
Other recent initiatives to reduce variation in care include a
strengthened requirement for national clinical audits, supported
and commissioned by the Healthcare Quality Improvement
Partnership (HQIP), to identify outlying trusts (those with values
>2 standard deviations (SDs from the mean for agreed performance
indicators for care delivery and outcomes)). Trusts will be
encouraged to reviewandunderstandoutlying treatment rates that
are ≥2 SDs from the mean and investigate when ≥3 SDs from the
mean as part of their internal quality monitoring. This process will
also support Care Quality Commission inspections using national
clinical audit data.29
The Getting it Right First Time (GIRFT) initiative has established an
ambitiousprogrammeof clinically ledassessments of breast surgical
services, including visits to trusts to understand and minimise
undue variations in care.30 GIRFT’s initial priorities are to reduce,
where possible, length of stay after breast surgery in linewithBritish
Association of Day Surgery guidelines, to encourage open access
follow-up to allowpatients to determinewhenandhow they interact
with breast teams, and reduce unnecessary hospital attendances,
operations, and tests. The GIRFT national report on breast surgery
is awaiting publication.
The National Audit of Breast Cancer in Older Patients has published
information on care pathways and treatment rates at trust level.11
The ready availability of data concerning care provision, that can
be individualised to a trust, team, or clinician is a priority for
national breast cancer audits and Public Health England.11 31 -33
Transparency and accountability to promote debate, discussion,
and audit are powerful tools in minimising the risk of substandard
practice. The formal involvement of patients in national audits and
in the governance activities of Public Health England is now routine
and is key to ensuring that outputs reflect patient priorities as well
as those of clinicians and policy makers.34
Variations in the care provided to patients with early breast cancer
have been described over decades, and it has been easy to attribute
these to poor data quality, case-mix differences, and patient choice.
Lack of accord concerning optimum levels of intervention, defining
unacceptable variation, and an inability to confirm causality from
observational data are also serious obstacles in trying to confront
this problem.
The management of breast cancer is closely studied in terms of
national audit and related initiatives, but the effect of variation in
care for other cancers is equally important to investigate and should
bea focus for cancer charities andprofessional groups.HQIPalready
supports key national audits in gastrointestinal, lung, and prostate
cancer.35
Key messages
• Substantial variations occur in the care of patients with early breast
cancer in the UK and may be leading to poorer outcomes
• Variation is of particular concern in management of older patients
• Patient factors cannot fully explain differences in treatment
• Data transparency and support for outliers may help reduce the gap
between evidence and its uniform implementation
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